PAK2 and lymphoma: Secondly, in our parallel paper, where we investigate the compensatory bypass pathways that become activated in c-Rel null and Eμ-Myc/RelaT505A lymphomas, we show that the RelA T505A lymphomas have increased sensitivity to drugs targeting the PI3K and PAK2 kinases [26].